Company profile: Exagen
1.1 - Company Overview
Company description
- Provider of diagnostic and monitoring tests for autoimmune rheumatic diseases, including AVISE CTD and AVISE Lupus for SLE diagnosis using CB-CAPs, AVISE SLE Monitor for disease activity, AVISE SLE Prognostic for risk of thrombosis, cardiovascular events, lupus nephritis and neuropsychiatric lupus, AVISE APS for antiphospholipid syndrome and thrombosis risk, and AVISE MTX to assess methotrexate exposure.
Products and services
- AVISE Lupus: Delivers a multi-marker diagnostic panel incorporating CB-CAPs to diagnose systemic lupus erythematosus, delivering comprehensive assessment with higher sensitivity than traditional tests
- AVISE CTD: Produces a CB-CAP–based diagnostic test for systemic lupus erythematosus, aiding differential diagnosis through cell-bound complement activation products
- AVISE SLE Monitor: Supplies an advanced six-biomarker panel for monitoring systemic lupus erythematosus activity, incorporating six specialized biomarkers to assess disease activity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Exagen
Veloxis Pharmaceuticals
HQ: Denmark
Website
- Description: Provider of specialty pharmaceuticals for kidney transplant patients, focused on the development and commercialization of ENVARSUS XR, a once-daily extended-release tacrolimus tablet to prevent organ rejection and facilitate switching from immediate-release formulations, and VEL-101, an investigational immunosuppressant blocking CD28-mediated T cell activation while preserving CTLA-4 functions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Veloxis Pharmaceuticals company profile →
Allergopharma
HQ: Germany
Website
- Description: Provider of allergen-specific immunotherapy for type 1 allergies such as hay fever and allergic asthma, offering Allergen Immunotherapy (AIT) to induce immunological tolerance, reduce symptoms, and prevent the progression of allergic diseases, along with diagnostics for IgE-mediated allergies to identify triggers for targeted treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allergopharma company profile →
Viela Bio
HQ: United States
Website
- Description: Provider of clinical-stage treatments for severe inflammation and autoimmune diseases, with a portfolio that selectively targets shared critical pathways at the root cause of disease; led by global leaders in inflammation and autoimmunity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Viela Bio company profile →
Ception Therapeutics
HQ: United States
Website
- Description: Provider of payroll management services, delivering customizable payroll solutions and advanced software for seamless, timely processing; comprehensive administration covering tax filings and employee deductions; payroll compliance with the latest laws and regulations; and consulting on best practices and audit assistance, allowing businesses to focus on growth.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ception Therapeutics company profile →
Ampio Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies targeting inflammatory conditions, including OA-201, a small molecule formulation explored as a potential treatment for osteoarthritis of the knee and other joints.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ampio Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Exagen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Exagen
2.2 - Growth funds investing in similar companies to Exagen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Exagen
4.2 - Public trading comparable groups for Exagen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →